Literature DB >> 24497532

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.

David D W Twa1, Fong Chun Chan, Susana Ben-Neriah, Bruce W Woolcock, Anja Mottok, King L Tan, Graham W Slack, Jay Gunawardana, Raymond S Lim, Andrew W McPherson, Robert Kridel, Adele Telenius, David W Scott, Kerry J Savage, Sohrab P Shah, Randy D Gascoyne, Christian Steidl.   

Abstract

The pathogenesis of primary mediastinal large B-cell lymphoma (PMBCL) is incompletely understood. Recently, specific genotypic and phenotypic features have been linked to tumor cell immune escape mechanisms in PMBCL. We studied 571 B-cell lymphomas with a focus on PMBCL. Using fluorescence in situ hybridization here, we report that the programmed death ligand (PDL) locus (9p24.1) is frequently and specifically rearranged in PMBCL (20%) as compared with diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma. Rearrangement was significantly correlated with overexpression of PDL transcripts. Utilizing high-throughput sequencing techniques, we characterized novel translocations and chimeric fusion transcripts involving PDLs at base-pair resolution. Our data suggest that recurrent genomic rearrangement events underlie an immune privilege phenotype in a subset of B-cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24497532     DOI: 10.1182/blood-2013-10-535443

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  98 in total

Review 1.  The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.

Authors:  Alexander Marx; John K C Chan; Jean-Michel Coindre; Frank Detterbeck; Nicolas Girard; Nancy L Harris; Elaine S Jaffe; Michael O Kurrer; Edith M Marom; Andre L Moreira; Kiyoshi Mukai; Attilio Orazi; Philipp Ströbel
Journal:  J Thorac Oncol       Date:  2015-10       Impact factor: 15.609

Review 2.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

Review 3.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

4.  Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.

Authors:  Min Shi; Margaretha G M Roemer; Bjoern Chapuy; Xiaoyun Liao; Heather Sun; Geraldine S Pinkus; Margaret A Shipp; Gordon J Freeman; Scott J Rodig
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

Review 5.  Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers.

Authors:  Siba El Hussein; Kenna R M Shaw; Francisco Vega
Journal:  Mod Pathol       Date:  2020-07-03       Impact factor: 7.842

Review 6.  Targeting the programmed death-1 pathway in lymphoid neoplasms.

Authors:  Chi Young Ok; Ken H Young
Journal:  Cancer Treat Rev       Date:  2017-02-11       Impact factor: 12.111

7.  Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

Authors:  Pier Luigi Zinzani; Vincent Ribrag; Craig H Moskowitz; Jean-Marie Michot; John Kuruvilla; Arun Balakumaran; Yayan Zhang; Sabine Chlosta; Margaret A Shipp; Philippe Armand
Journal:  Blood       Date:  2017-05-10       Impact factor: 22.113

Review 8.  Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

Authors:  Kieron Dunleavy; Wyndham H Wilson
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

Review 9.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

Review 10.  Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.

Authors:  Jinfang Zhang; Fabin Dang; Junming Ren; Wenyi Wei
Journal:  Trends Biochem Sci       Date:  2018-10-01       Impact factor: 13.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.